GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study of Novel Treatment Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma.

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Domvanalimab
Drug: Zimberelimab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 100

Registration Number: NCT06727565

Study of Obeldesivir as Postexposure Prophylaxis for Marburg Virus Disease

Phase 2

Not yet recruiting

Conditions: Postexposure Prophylaxis Marburg Virus Disease

Interventions: Drug: obeldesivir

First Posted Date: 2024-11-12

Last Posted Date: 2024-12-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 400

Registration Number: NCT06682234

A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain

Not yet recruiting

Conditions: Breast Cancer

First Posted Date: 2024-11-12

Last Posted Date: 2024-12-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 50

Registration Number: NCT06683482

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Phase 3

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: ISL/LEN
Drug: B/F/TAF
Drug: PTM B/F/TAF
Drug: PTM ISL/LEN

First Posted Date: 2024-10-08

Last Posted Date: 2024-12-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 600

Registration Number: NCT06630286

Locations: 🇺🇸
Pueblo Family Physicians, Phoenix, Arizona, United States
🇺🇸
Kaiser Permanente Southern California, Los Angeles, California, United States
🇺🇸
BIOS Clinical Research, Palm Springs, California, United States

and more 47 locations

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

Phase 3

Recruiting

Conditions: HIV-1-Infection

Interventions: Drug: ISL/LEN
Drug: Antiretroviral Combinations

First Posted Date: 2024-10-08

Last Posted Date: 2024-12-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 600

Registration Number: NCT06630299

Locations: 🇺🇸
Pueblo Family Physicians, Phoenix, Arizona, United States
🇺🇸
Vv-Tmf-5366229, Los Angeles, California, United States
🇺🇸
Ruane Clinical Research Group, Los Angeles, California, United States

and more 32 locations

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Phase 2

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: GS-1720
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Drug: GS-1720/GS-4182 FDC
Drug: GS-4182
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

First Posted Date: 2024-09-26

Last Posted Date: 2024-12-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 675

Registration Number: NCT06613685

Locations: 🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸
Orlando Immunology Center, Orlando, Florida, United States

and more 11 locations

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Phase 2

Recruiting

Conditions: RSV Infection

Interventions: Drug: Obeldesivir
Drug: Obeldesivir Placebo

First Posted Date: 2024-09-05

Last Posted Date: 2024-12-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 240

Registration Number: NCT06585150

Locations: 🇺🇸
Allianz Research Institute- Colorado, Aurora, Colorado, United States
🇺🇸
UHC Research, LLC, Doral, Florida, United States
🇺🇸
Aga Clinical Trials, Hialeah, Florida, United States

and more 97 locations

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Recruiting

Conditions: Weight Management

Interventions: Drug: GS-4571
Drug: Placebo
Drug: Omeprazole

First Posted Date: 2024-08-20

Last Posted Date: 2024-11-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 134

Registration Number: NCT06562907

Locations: 🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Phase 2

Recruiting

Conditions: HIV-1-Infection

Interventions: Drug: GS-1720/GS-4182 FDC
Drug: GS-1720
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC
Drug: GS-4182

First Posted Date: 2024-08-09

Last Posted Date: 2024-10-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 675

Registration Number: NCT06544733

Locations: 🇺🇸
North Texas Infectious Diseases Consultants, PA, Dallas, Texas, United States
🇵🇷
Proyecto ACTC, San Juan, Puerto Rico
🇺🇸
Ruane Clinical Research Group, Los Angeles, California, United States

and more 31 locations

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Phase 2

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: Lenacapavir
Drug: BIC/LEN FDC

First Posted Date: 2024-08-01

Last Posted Date: 2024-12-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 75

Registration Number: NCT06532656

Locations: 🇿🇦
Setshaba Research Centre, Soshanguve, South Africa
🇿🇦
Stellenbosch University, Worcester, South Africa
🇿🇦
Perinatal HIV Research Unit, Johannesburg, Gauteng, South Africa

and more 6 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy